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Summary
Doxorubicin is an anthracycline DNA intercalator that is
among themost commonly used anticancer drugs [1]. Doxo-
rubicin causes DNA double-strand breaks in rapidly dividing
cells, although whether it also affects general chromatin
properties is unknown. Here, we use a metabolic labeling
strategy to directly measure nucleosome turnover [2] to
examine the effect of doxorubicin on chromatin dynamics
in squamous cell carcinoma cell lines derived from geneti-
cally defined mice. We find that doxorubicin enhances
nucleosome turnover around gene promoters and that turn-
over correlates with gene expression level. Consistent with a
direct action of doxorubicin, enhancement of nucleosome
turnover around promoters gradually increases with time
of exposure to the drug. Interestingly, enhancement occurs
both in wild-type cells and in cells lacking either the p53
tumor suppressor gene or the master regulator of the DNA
damage response, ATM, suggesting that doxorubicin action
on nucleosome dynamics is independent of the DNA dam-
age checkpoint. In addition, another anthracycline drug,
aclarubicin, shows similar effects on enhancing nucleo-
some turnover around promoters. Our results suggest that
anthracycline intercalation promotes nucleosome turnover
around promoters by its effect on DNA topology, with
possible implications for mechanisms of cell killing during
cancer chemotherapy.
Results and Discussion
Nucleosomes Turnover around Gene Promoters
In order to directly measure nucleosome turnover, our lab
developed the CATCH-IT (covalent attachment to tags to
capture histones and identify turnover) method [2], whereby
newly synthesized proteins are labeled with a methionine
(Met) analog, azidohomoalanine (Aha), which allows coupling
to biotin for affinity capture of purified chromatin. Extraction
of DNA from the resulting newly synthesized nucleosomes
is followed by genome-wide mapping using tiling microarrays
or short-read massively parallel sequencing [3]. We previously
applied CATCH-IT to investigate nucleosome changes during
the heat-shock response in Drosophila cells and discovered
that global changes in turnover were associated with tran-
scription without corresponding changes in nucleosome
occupancy [4]. The high sensitivity of the CATCH-IT assay
to changes in genome-wide chromatin dynamics encouraged
us to examine other possible chromatin perturbations
using CATCH-IT, such as those that are induced by*Correspondence: cjkemp@fhcrc.org (C.J.K.), steveh@fhcrc.org (S.H.)chemotherapeutic agents. Because doxorubicin (also called
adriamycin) is a widely used anticancer drug that interacts
directly with DNA, we wondered whether chromatin dynamics
are affected by doxorubicin in cancer cells. Accordingly, we
applied CATCH-IT to genetically defined mouse squamous
cell carcinoma (SCC) cell lines before and after doxorubicin
treatment. These cell lines were derived from SCCs induced
by the two-step 7,12-dimethylbenz[a]anthracene (DMBA) and
12-O-tetradecanoylphorbol-13-acetate (TPA) carcinogenesis
protocol applied to the dorsal skin of mice [5, 6]. Using this
protocol, tumors consistently harbor activating mutations in
the oncogene Hras1.
We first applied CATCH-IT to mouse SCC cells [7].
Sequencing of exons 2–11 of the p53 gene revealed no muta-
tions, and these cells were designated p53 wild-type (WT)
MSCC-CK1 cells. CATCH-IT and input DNAs were labeled
with Cy5 and Cy3, respectively, and were hybridized together
to high-density mouse promoter arrays. Gene 50 or 30 ends
analysis was performed by aligning all annotatedmouse genes
at transcriptional start sites (TSSs) or transcriptional end sites
(TESs) and calculating average nucleosome turnover in 50 bp
intervals over a range of 3 kb upstream and 3 kb downstream,
using a 200 bp sliding window. As shown in Figure 1A, nucle-
osome turnover ismost rapid around TSSs, decreasing toward
gene bodies, consistent with results in Drosophila S2 cells [2].
Additionally, strong enrichment was observed upstream of
TSSs (Figure 1A). This double-peak pattern is in good agree-
ment with profiles of H3.3, H2A.Z, and many histone modifica-
tions associated with active genes in both mouse and human
cells [8–11], possibly driven by bidirectional transcription of
mammalian promoters. Examples of CATCH-IT profiles are
shown for two transcriptionally active genes (p21 and
Mdm2), where strong CATCH-IT signals were observed
around TSSs in the Aha sample but not in the Met control
(Figure 1B).
Nucleosome Turnover Correlates with Transcription
We had previously shown that nucleosome turnover is corre-
lated with gene expression in Drosophila cells [2, 4]. To ascer-
tain whether there is a similar relationship between turnover
and gene expression in SCC cells, we used microarrays to
obtain gene expression profiles. We first compared untreated
SCC cells with cells treated with 0.34 mM doxorubicin for 18 hr
[12]. Of the total 18,233 genes, only 192 genes were upregu-
lated more than 2-fold with doxorubicin treatment, and 61
geneswere downregulatedmore than 2-fold. Although aminor
effect on gene expression was detected upon doxorubicin
treatment, Gene Ontology (GO) analysis revealed that genes
related to the DNA damage response and cell-cycle arrest
were significantly upregulated (see Figure S1 available online).
To examine the relationship between nucleosome turnover
and gene expression, we grouped genes into five quintiles ac-
cording to their expression levels and performed 50 ends anal-
ysis for the genes in each quintile. In addition, we generated a
heatmap of nucleosome turnover over the 63 kb region sur-
rounding the TSSs. We found that nucleosome turnover is
correlated with gene expression level before and after doxoru-
bicin treatment, consistent with previous findings in
Drosophila cells [2, 4] (Figures 2A and 2B). Therefore,
0 1 2 3-1
-2-3 (kb)
0
0.1
0.2
-0.1
-0.3
Lo
g2
 (C
AT
CH
-IT
/in
pu
t)
Aha
Met
A
B
Lo
g2
 (C
AT
CH
-IT
/in
pu
t)
Aha
Met
Aha
Met 0
3.0
-3.0
0
3.0
-3.0
0
3.0
-3.0
0
3.0
-3.0
0 1 2 3-1-2-3 (kb)
p21
Mdm2
-0.2
Figure 1. CATCH-IT Analysis of Mouse WT SCC Cells
(A) Average enrichment of CATCH-IT signals at the 50 ends of 16,797 genes
in WT SCC cells (azidohomoalanine [Aha], red curve; methionine [Met], blue
curve). Data are shown as log2 of the average signal ratio between CATCH-
IT and input fractions for 3 kb upstream and 3 kb downstream of the tran-
scription start site (TSS; arrow). Data were plotted using a 200 bp sliding
window.
(B) CATCH-IT profiles of the promoter regions (63 kb around the TSS) of two
transcriptional active genes (p21 andMdm2, black boxes) are shown. Data
are presented as log2 ratio between CATCH-IT and input fractions. The
TSSs and the transcription direction are marked by arrows. Aha tracks are
shown in red; Met tracks are shown in blue.
See also Figure S1.
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783nucleosome turnover is likely to be coupled to transcription in
mammalian cells, as it is in Drosophila.
Turnover Increases with Doxorubicin Treatment
To determine whether doxorubicin treatment affects chro-
matin dynamics, we displayed the difference in nucleosome
turnover between treated and untreated cells around 50 end
and 30 end as a heatmap, ordered by decreasing gene expres-
sion. Interestingly, doxorubicin treatment resulted in
increased nucleosome turnover almost exclusively at active
genes, with the highest levels seen on both sides of the most
active gene promoters but not around 30 ends (Figures 3A
and S2A; Table S1). To identify the genes showing enhance-
ment or reduction in turnover in an unbiased manner, we per-
formed unsupervised k-means clustering to separate genesinto two groups. About 43% of all mouse annotated genes
showed enhancement of nucleosome turnover after doxoru-
bicin treatment (group 1) (Figure 3A). Because only w1% of
all genes showed more than a 2-fold increase in gene expres-
sion with doxorubicin treatment, we conclude that this global
enhancement in nucleosome turnover around active gene
promoters is not a consequence of doxorubicin-induced
transcriptional upregulation but is rather a general feature of
transcriptional activity in doxorubicin-treated cells.
It is thought that intercalation of doxorubicin into DNA traps
topoisomerase II when it is covalently bound to DNA during
double-strand cleavage, and that this results in double-strand
breaks that must be repaired to avoid chromosome breakage
[13]. These breaks induce a strong DNA damage response
leading to upregulation of the p53 transcription factor and
induction of cell-cycle arrest or apoptosis [12, 14]. Cells lack-
ing p53 are defective in cell-cycle arrest or apoptosis following
DNA damage. Because p53 is frequently mutated in human
SCC [15, 16] and it is a central player in the cellular response
to doxorubicin [17–19], we asked whether doxorubicin-
induced increases in nucleosome turnover are dependent on
the p53 protein. For this, we developed anSCC cell line derived
from a mouse carrying conditional deletion in the p53 gene [7,
20], designated MSCC-CK4 Trp532/2 (Cre + Trp53 lox/lox)
referred to as p532/2. The cre/lox-mediated deletion of p53
was confirmed by RT-PCR (Figure S2B). In addition, induction
of awell-known p53 transcriptional target, p21/WAF1 [21], was
observed in p53WT but not in p532/2 SCC cells after 18 hr of
doxorubicin treatment (Figure S2C), further confirming the
absence of p53 in p532/2 SCC cells. Furthermore, doxorubicin
treatment caused a cell-cycle arrest in the p53 WT, demon-
strating that p53 is active in these cells (Figure S2D). We per-
formed CATCH-IT on p532/2 SCC cells and generated gene
expression profiles before and after doxorubicin treatment
for 18 hr, as we had done for p53 WT SCC cells. Similar to
the results of expression profiling for p53 WT cells, only 119
of 18,233 genes were upregulated more than 2-fold, and only
97 genes were downregulated more than 2-fold. As expected
for p532/2 cells, GO analysis revealed a lack of DNA-damage
response genes among those significantly upregulated (Fig-
ure S1). Gene 50 ends analysis for the genes in each expression
quintile and heatmaps ordered by gene expression level were
plotted for doxorubicin-treated and untreated p532/2 SCC
cells. These plots revealed that in p532/2 SCC cells, nucleo-
some turnover correlates with gene expression level whether
or not the cells were treated with doxorubicin (Figures 2C
and 2D).
Similar to what we had observed for p53 WT SCC
cells, nucleosome turnover increased around active gene pro-
moters, but not around 30 ends, after doxorubicin treatment in
about 53% of all mouse annotated genes (group 1) in p532/2
SCC cells (Figure 3B; Table S1). Therefore, p53 is not required
for elevation of nucleosome turnover by doxorubicin.
In the above experiments, enhancement of nucleosome
turnover was assayed 18 hr after doxorubicin treatment, and
it is possible that effects on nucleosome turnover were indirect
consequences of intermediate events, such as a global DNA
damage response or induction of genes that themselves
enhance nucleosome turnover. If, instead, doxorubicin inter-
calation directly causes nucleosome turnover, then we would
expect to see turnover changes gradually increase with time
of exposure to the drug. Therefore, we treated WT SCC cells
with doxorubicin and performed CATCH-IT on samples at 0,
1, 4, 8, and 24 hr later. As expected for a direct effect of
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Figure 2. Nucleosome Turnover Correlates with Gene Expression Level in Both p53 WT and p532/2 SCC Cells before and after Doxorubicin Treatment
Left panels: geneswere grouped into five quintiles according to gene expression level (from highest [1st, 20th percentile] to lowest [5th, 20th percentile]) in p53
WT SCC cells. Ends analysis of average CATCH-IT signals 6 3 kb surrounding the TSS (arrow) was performed for each quintile. Data were plotted using a
200 bp sliding window. Right panels: CATCH-IT data are presented as heatmaps of the 63 kb surrounding the TSS using Java TreeView. Genes were
ordered by decreasing gene expression level in p53 WT SCC cells (A), doxorubicin (Doxo)-treated p53 WT SCC cells (B), p532/2 SCC cells (C), and
Doxo-treated p532/2 SCC cells (D). The average of two independent experiments is shown in each panel. There is a highly significant excess of genes
with an increase in turnover for both WT and p532/2 cells (p < 102307). See also Table S1.
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784doxorubicin on nucleosome turnover, we found that doxoru-
bicin enhanced nucleosome turnover gradually over the time
course (Figures 4A, 4B, and S3; Table S1) .
Enhancement of Turnover Is Independent of the DNA
Damage Response
The DNA double-strand breaks induced by doxorubicin treat-
ment activate the ATM kinase that is the master regulator of
the DNA damage response [22]. Among other targets, ATM
phosphorylates p53 [23] and H2A.X [24] at DNA double-strand
breaks and recruits repair proteins to religate the breaks
[25–27]. Therefore, we wondered whether ATM is required
for the genome-wide enhancement of nucleosome turnover
upon doxorubicin treatment. We derived an ATM2/2 SCC cell
line, MSCC-CK104, from a DMBA/TPA-induced SCC origi-
nating in a mouse with a germline mutation in ATM [7].
CATCH-IT was performed at 0, 1, 4, 8, and 24 hr after doxoru-
bicin treatment. As shown in Figures 4C and 4D, nucleosome
turnover increased gradually upon doxorubicin treatment,
indicating that doxorubicin-induced elevation of nucleosome
turnover is independent of ATM (Table S1). We conclude that
the DNA damage response is not required for the increase in
nucleosome turnover induced by doxorubicin.
Aclarubicin Also Enhances Nucleosome Turnover
Doxorubicin is thought to trap covalently bound topoisomer-
ase II at DNA double-strand breakage sites to prevent religa-
tion especially when low doses (<1 mM) are used [28].
Breakage by this mechanism is thought to rapidly induce the
DNA damage response [19]. To investigate whether topoisom-
erase II-mediated DNA double-strand breakage is required for
the enhancement of nucleosome turnover around promoters,
we used another anthracycline drug, aclarubicin (also calledaclacinomycin A), which is a DNA intercalator that inhibits
topoisomerase activity prior to cleavage, thus not directly
resulting in DNA breakage [28]. We first treated WT SCC cells
with a series of doses (0.1, 0.2, 0.4, 0.8, 1.6, 3.2, and 6.4 mM) for
24 hr to test for toxicity of aclarubicin. Cell death was observed
when treated with 0.8 mM or higher doses (data not shown),
consistent with the toxicity seen in human small-cell lung
cancer cell lines [29]. CATCH-IT was performed on WT SCC
cells after 24 hr aclarubicin treatment at three different doses
(0.1, 0.2, and 0.4 mM). Similar to what we had observed for
doxorubicin treatment, aclarubicin enhanced nucleosome
turnover around promoters of active genes, especially down-
stream of promoters (Figures 4E and 4F; Table S1). We
conclude that direct topoisomerase II-mediated DNA
breakage is not required for the observed enhancement of
nucleosome turnover.
Conclusions
In summary, we have identified a novel role of widely used
chemotherapeutic anthracycline drugs: enhancement of
nucleosome turnover around promoters of active genes.
This enhancement occurs despite almost undetectable
increases in gene expression and is seen in cells that lack
both p53 and ATM, which have both been linked to doxoru-
bicin sensitivity [18]. What is the mechanism by which doxoru-
bicin or aclarubicin induces nucleosome turnover around
active gene promoters? As DNA intercalators, anthracycline
drugs untwist DNA, which in a topologically constrained situ-
ation results in positive supercoiling. During transcription initi-
ation, melting of DNA by RNA polymerase would cause the
propagation of positive supercoiling on both sides of the
promoter, resulting in nucleosome unwrapping [30]. Melting
would facilitate intercalation of anthracyclines, thus
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Figure 3. Nucleosome Turnover Is Enhanced
around Promoters upon Doxorubicin Treatment
in Both p53 WT and p532/2 SCC Cells
Doxorubicin treatment enhances nucleosome
turnover around the transcription start site
(TSS), but not around the transcription end site
(TES). The difference in nucleosome turnover
before and after doxorubicin treatment (Doxo 2
Ctl) in p53WT (A) or p532/2 (B) SCC cells is shown
as 50 and 30 end heatmaps either by ordering
genes according to gene expression level in un-
treated SCC cells (left) or by unsupervised
k-means clustering of TSS 6 3 kb data to sepa-
rate genes into two groups (right). Ctl, control
with no doxorubicin treatment. The average of
two independent experiments is shown. See
also Figure S2.
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785enhancing positive supercoil propagation and nucleosome
unwrapping. In addition, topoisomerases are able to relax
positively supercoiled DNA supercoils; thus, inhibition of
topoisomerase II by doxorubicin or aclarubicin may also
elevate positive torsional stress generated by RNA polymer-
ase II movement [31, 32]. In either case, enhancement of
unwrapping should increase nucleosome eviction and
replacement that normally occur during active transcription.
In this way, the intercalation of anthracyclines will increase
turnover independent of changes in gene expression or the
DNA damage response.
Based on our new findings, we speculate that enhancement
of nucleosome turnover at promoters by anthracycline drugs
can result in increased DNA fragility around promoters. Loss
of nucleosomes at human telomeres is thought to be respon-
sible for DNA damage and genome instability associated
with alternative lengthening of telomeres (ALT) caused by mu-
tations in the H3.3/DAXX/ATRX nucleosome assembly
pathway [33]. Considering that the doses we used in our ex-
periments (0.1–0.4 mM) aremuch lower than doses used in can-
cer chemotherapy (w5 mM; [34]), DNA fragility and breakage
caused by nucleosome turnover around promoters might
contribute to cancer cell killing. Our model might also account
for the observation that aclarubicin causes DNA damage in a
Drosophila in vivo assay [35], despite its inhibition of topo-
isomerase II activity prior to DNA cleavage. Understanding
the molecular effects of anthracycline drug treatment on
nucleosome dynamics may provide new insights into the
design of anticancer therapies that combine new classes of
drugs that target chromatin regulators with traditional chemo-
therapeutic agents.
Experimental Procedures
Cell Lines
Squamous cell carcinomaswere induced by treatment with the carcinogens
DMBA and TPA on the dorsal skin of mice carrying germline mutations in
ATM or p53, as well as in WTmice [7]. Tumors arising from this protocol uni-
formly harbor activatingmutations in the oncogeneHras1. When tumors un-
derwent malignant papilloma-to-carcinoma conversion, tumors were
explanted into culture. Carcinoma cells from the above genotypes were
cultured and frozen down at early passage.
Tissue Culture
Mouse SCC cell lines (MSCC-CK1, WT; MSCC-CK4, p532/2; MSCC-CK104,
ATM2/2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM)(#11965-092; Invitrogen) supplemented with 10% FBS and 1% penicillin-
streptomycin at 37C.Cell-Cycle Analysis
WT SCC cells after 18 hr doxorubicin treatment were washed in 13 PBS
and fixed in 70% ethanol for about 2 hr. After fixation, cells were washed
in 13 PBS, resuspended in 1 ml of propidium iodide (PI) staining solution
(13 PBS, 0.1% Triton X-100, 20 mg/ml PI, 100 mg/ml DNase-free RNase
A), and incubated at room temperature for 30 min. Flow cytometric
analysis was performed utilizing a BD FACS Canto II (Becton Dickinson).
Cell-cycle analysis was performed with CellQuest software (Becton
Dickinson).CATCH-IT
CATCH-IT was performed as described previously [2] with some modifica-
tions. Briefly, tissue culture medium was replaced with DMEM without
methionine (catalog #21013-024; Invitrogen) supplemented with 13 gluta-
mine, 0.2 mM L-cysteine, 10% FBS, and 1% penicillin-streptomycin, and
cells were grown at 37C for starvation for 30 min, followed by 30 min incu-
bation at 37C with 4 mM azidohomoalanine (catalog #63669; AnaSpec)
added to the media. Cells were then harvested, washed with 13 PBS,
and resuspended in ice-cold TM2 buffer (10 mM Tris [pH 7.5], 2 mM
MgCl2). Cells were lysed using 0.2% of NP-40 and nuclei were isolated, fol-
lowed by digestion of micrococcal nuclease for 10 min to produce mostly
mononucleosomes. Biotin coupling, chromatin extraction, streptavidin
pull-down, urea wash, and DNA isolation were then performed as described
previously [2].Microarray Preparation and Data analysis
Input and CATCH-IT DNAs were amplified using a whole-genome amplifica-
tion kit (catalog #WGA2; Sigma-Aldrich), followed by labeling using Cy3 and
Cy5 heptamers according to the Roche Nimblegen labeling protocol.
Labeled samples were hybridized together to mouse 2.1-million probe pro-
moter arrays (Roche Nimblegen). For data analysis, arrays were corrected
for dye bias [36], and ends analysis, k-mean clustering, and heatmaps
were performed as described previously [37].RNA Isolation, RT-PCR, and Gene Expression Analysis
Total RNAwas isolated using the QIAGEN RNeasy kit. For RT-PCR analysis,
first-strand cDNA was synthesized using SuperScript II Reverse Transcrip-
tase (Invitrogen), followed by PCR using a set of p53 primers: forward,
50-GCTTCTCCGAAGACTGGATGACT-30; reverse, 50-GATTGTGTCTCAGCC
CTGAAGTCA-30. For expression array analysis, first-strand and second-
strand cDNAs were synthesized and double-strand cDNAswere labeled ac-
cording to the NimbleGen protocol for expression arrays. Labeled samples
were hybridized to NimbleGen mouse 385K expression arrays. All samples
were normalized together using the robust multichip average (RMA) anal-
ysis function provided byDEVA software (NimbleGen). GO analysis was per-
formed by using GeneCodis [38–40].
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Figure 4. Both Doxorubicin and Aclarubicin
Enhance Nucleosome Turnover around Pro-
moters of Active Genes
(A, C, and E) Ends analysis of average enrichment
of CATCH-IT signals 6 3 kb surrounding the TSS
(arrow) in ATM WT (A) and ATM2/2 (C) SCC cells
at 0, 1, 4, 8, and 24 hr after doxorubicin treatment,
or in ATM WT SCC cells before and after 24 hr
aclarubicin treatment at 0.1, 0.2, and 0.4 mM (E).
Data were plotted using a 200 bp sliding window.
(B, D, and F) Differences in nucleosome turnover
between doxorubicin-treated ATM WT (B) or
ATM2/2 (D) SCC cells (treated for 1, 4, 8, or
24 hr) and untreated ATM WT or ATM2/2 SCC
cells (0 hr) or between aclarubicin-treated ATM
WT (treated at 0.1, 0.2, and 0.4 mM) and untreated
ATM WT (control) SCC cells (F) are shown as
heatmaps. Genes were ordered by decreasing
gene expression in ATM WT SCC cells without
doxorubicin or aclarubicin treatment. Except for
the 1 hr time points, there is a highly significant
excess of genes with an increase in turnover
(Table S1).
See also Figure S3.
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